Key result
Intravenous disopyramide significantly shortened sinus cycle length and prolonged atrial and ventricular effective refractory periods, with maximal effects at 5 minutes.
Why the study?
Does intravenous disopyramide alter electrophysiological parameters in fasting, unpremedicated patients?
Does intravenous disopyramide alter electrophysiological parameters in fasting, unpremedicated patients?
Intravenous disopyramide demonstrates quinidine-like electrophysiological effects, prolonging refractory periods but potentially worsening intraventricular conduction in patients with pre-existing His Purkinje disease.
No takes yet. Share an insight, caveat, or question.
Requires caution in patients with His-Purkinje disease; leaves open whether EP changes affect clinical outcomes.
Ross et al. (1978) studied this question. Disopyramide phosphate was evaluated on Electrophysiological effects. Intravenous disopyramide significantly shortened sinus cycle length and prolonged atrial and ventricular effective refractory periods, with maximal effects at 5 minutes.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: